Data reinforce the potential of NTLA-2002 to eliminate angioedema attacks in people living with hereditary angioedema (HAE) after a single dose A single dose of NTLA-2002 led to 95% mean reduction in monthly HAE attack rate with 9 of 10 patients remaining completely attack free following the 16-week primary observation period through the latest follow-up reportedNTLA-2002 was well-tolerated at all dose levels Second NEJM publication of initial clinical data for Intellia's in vivo CRISPR-based investigationa ...

A downtrend has been apparent in Intellia Therapeutics, Inc. (NTLA) lately with too much selling pressure. The stock has declined 19.1% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical in ...

Companies focusing on developing gene editing therapies have made significant progress over the past year. However, that has done little to keep Intellia Therapeutics (NTLA -1.63%) afloat. The biotech's stock has substantially lagged the broader market over the trailing 12 months. Still, Intellia Therapeutics has several promising candidates in the pipeline. If the company can record solid clinical and regulatory progress from here on out, its stock could rebound. Does Intellia Therapeutics have what it tak ...

SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa Positive recommendation received from the Data Safety Monitoring Board (DSMB) enabling progression to highest dose of Part 1 of the PRODYGY trialFavorable safety and tolerability profiles observed with first two SPVN06 doses across six patients (three patients per cohort)Exploration of SPVN06 in geographic atrophy to begin in 2024 Paris, 24 January 2024 – SparingVision ("the Company"), a clinical-stage gen ...

One stock that might be an intriguing choice for investors right now is Intellia Therapeutics, Inc. (NTLA) . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably t ...

Core priorities through 2026 include completion of Phase 3 study and BLA submission for NTLA-2002, completion of patient enrollment in the pivotal study of NTLA-2001, clinical validation of modular in vivo gene insertion technology and advancement of earlier-stage pipeline and platform innovations On track to dose the first patient in the pivotal Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy in Q1 2024Expect to present results from the Phase 2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37766 INTELLIA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 36-4785571 (State or Other Jurisdict ...

Funding and Financial Overview - Intellia Therapeutics has raised approximately $2,404.8 million since inception through various funding methods, including IPOs and collaboration agreements[112]. - All revenue to date has been collaboration revenue, indicating a focus on strategic partnerships for development and commercialization[112]. - Collaboration revenue decreased by $0.4 million to $13.6 million for the three months ended June 30, 2023, compared to $14.0 million for the same period in 2022[137]. - Collaboration revenue increased by $0.9 million to $26.2 million for the six months ended June 30, 2023, compared to $25.3 million in 2022[142]. - The net loss for the six months ended June 30, 2023, was $226.8 million, a decrease of $20.7 million compared to a net loss of $247.6 million in 2022[141]. - Net cash used in operating activities was $199.7 million for the six months ended June 30, 2023, compared to $164.9 million for the same period in 2022, reflecting increased spending in research and development[159]. - The company expects its current cash and funding from collaborations to cover operating expenses and capital requirements beyond the next 24 months[156]. - The company issued 35,349 shares at an average price of $44.58 per share during the six months ended June 30, 2023, resulting in net proceeds of $1.5 million[152]. - Cash used in investing activities was $156.8 million for the six months ended June 30, 2023, primarily due to purchases of marketable securities[161]. - As of June 30, 2023, the company had $1,072.1 million in cash, cash equivalents, and marketable securities[147]. Research and Development Progress - The lead in vivo candidates, NTLA-2001 and NTLA-2002, are the first CRISPR/Cas9-based therapies administered systemically for precision gene editing in humans[113]. - NTLA-2001 aims to be the first single-dose treatment for ATTR amyloidosis, with an IND application planned for submission to the FDA in September 2023[116]. - NTLA-2002 has shown a 95% mean reduction in monthly attack rate in a Phase 1/2 study, with a median follow-up duration of 9.0 months[121]. - NTLA-3001 is designed to restore functional A1AT protein levels after a single dose, with a Clinical Trial Application planned for submission by the end of 2023[123]. - NTLA-2003 aims to halt liver disease progression by inactivating the SERPINA1 gene, with IND-enabling activities expected to be completed by the end of 2023[124]. - The company is advancing multiple ex vivo programs for immuno-oncology and autoimmune diseases, alongside its in vivo initiatives[113]. - The company plans to initiate a global pivotal Phase 3 study for NTLA-2001 for ATTR-CM by the end of 2023, pending regulatory feedback[116]. Expenses and Financial Performance - Research and development expenses increased by $25.1 million to $115.3 million for the three months ended June 30, 2023, representing a 28% increase compared to $90.2 million in 2022[138]. - Research and development expenses decreased by $10.9 million to $212.4 million for the six months ended June 30, 2023, compared to $223.3 million in 2022, a 5% decrease[143]. - General and administrative expenses rose by approximately $8.5 million to $30.7 million for the three months ended June 30, 2023, compared to $22.1 million in 2022[139]. - General and administrative expenses increased by $13.6 million to $58.1 million for the six months ended June 30, 2023, compared to $44.5 million for the same period in 2022[144]. - Employee-related expenses increased by $7.2 million during the six months ended June 30, 2023, primarily due to personnel growth[142]. - Stock-based compensation increased by $8.3 million during the six months ended June 30, 2023, driven by a larger workforce[142]. - Total operating expenses for the six months ended June 30, 2023, were $270.5 million, a slight increase of $2.7 million compared to $267.8 million in 2022[141]. Technology and Innovation - Intellia's proprietary CRISPR/Cas9 technology includes base editing and DNA writing capabilities, expanding its therapeutic applications[109]. - The company expects expenses to increase in 2023 as it continues to grow its research and development team and advance clinical programs[153]. - The company is eligible to earn milestone payments and royalties under collaborations with Novartis, SparingVision, and ONK, among others, but the timing of these payments is uncertain[148]. - The company does not have any foreign currency or derivative financial instruments, and inflation did not materially affect its results during the six months ended June 30, 2023[167].

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Ian Karp - Senior Vice President, Investor Relations and Corporate Communications John Leonard - Chief Executive Officer David Lebwohl - Chief Medical Officer Laura Sepp-Lorenzino - Chief Scientific Officer Glenn Goddard - Chief Financial Officer Conference Call Participants Joseph Thome - TD Cowen Maury Raycroft - Jefferies Yanan Zhu - Wells Fargo Securities Dae Gon Ha - Stifel Liisa Bayko ...

l ■ l IIII Immuno-oncology Autoimmune diseases In Vivo Leader: First to Demonstrate Systemic CRISPR Gene Editing in Humans 12 * Lead development and commercial party; ** Rights to certain in vivo targets; *** Milestones & royalties only AATD: alpha-1 antitrypsin deficiency; CAR-T: chimeric Antigen Receptor T Cells; HSC: hematopoietic stem cells; OSC: ocular stem cells; TCR: T cell receptor Capable of delivering to multiple tissue types for various therapeutic applications | --- | --- | --- | --- | |-------| ...